Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07248144 plus fulvestrant versus everolimus plus endocrine therapy in HR-positive HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor therapy
jRCT2031250245Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of prifetrastat, fulvestrant, everolimus and exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Aug 2025; status: recruiting.
02
Drugs
prifetrastatfulvestranteverolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031250245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250245.